Albers Jeffrey W.
SEC insider (Form 3/4/5 filer). CIK 0001638474. Director at Spyre Therapeutics, Inc. (SYRE) and 2 other issuers. 43 reported Form 4/5 transactions since Sep 2024; latest on Aug 7, 2026. Located in WALTHAM, MA.
Companies Albers Jeffrey W. has filed insider reports for
- Spyre Therapeutics, Inc. (SYRE): Director
- Kymera Therapeutics, Inc. (KYMR): Director
- Blueprint Medicines Corp (BPMC): Director
Albers Jeffrey W.
CIK: 0001638474
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (43 total)
- Aug 7, 2026SYRE
Spyre Therapeutics, Inc.
ExerciseDirect5K shares at avg. $10.39$52K - Aug 7, 2026SYRE
Spyre Therapeutics, Inc.
SaleIndirect10K shares at avg. $104.68$1.0M - Aug 7, 2026SYRE
Spyre Therapeutics, Inc.
SaleDirect5K shares at avg. $104.47$522K - Aug 7, 2026SYRE
Spyre Therapeutics, Inc.
SaleIndirect8K shares at avg. $104.38$835K - Jun 24, 2026KYMR
Kymera Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
6.1K shares- - May 27, 2026SYRE
Spyre Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
8K shares- - Dec 8, 2025KYMR
Kymera Therapeutics, Inc.
ExerciseDirect5K shares at avg. $14.18$71K - Dec 8, 2025KYMR
Kymera Therapeutics, Inc.
SaleDirect2.7K shares at avg. $89.32$245K - Dec 8, 2025KYMR
Kymera Therapeutics, Inc.
SaleDirect2.3K shares at avg. $90.30$203K - Oct 13, 2025KYMR
Kymera Therapeutics, Inc.
SaleDirect5K shares at avg. $59.19$296K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 7, 2026 |  SYRE Spyre Therapeutics, Inc. | Exercise | 5,000 | $10.39 | $51,950 | Direct |
| Aug 7, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 10,000 | $104.68 | $1,046,800 | Indirect |
| Aug 7, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 5,000 | $104.47 | $522,350 | Direct |
| Aug 7, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 8,000 | $104.38 | $835,040 | Indirect |
| Jun 24, 2026 |  KYMR Kymera Therapeutics, Inc. | Award Stock Option (Right to Buy) | 6,068 | - | - | Direct |
| May 27, 2026 | SYRE Spyre Therapeutics, Inc. | Award Stock Option (Right to Buy) | 8,026 | - | - | Direct |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | Exercise | 5,000 | $14.18 | $70,900 | Direct |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | Sale | 2,748 | $89.32 | $245,460 | Direct |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | Sale | 2,252 | $90.30 | $203,363 | Direct |
| Oct 13, 2025 | KYMR Kymera Therapeutics, Inc. | Sale | 5,000 | $59.19 | $295,949 | Direct |
1-10 of 43 transactions